Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Meehyun Ko; Sangeun Jeon; Wang Shick Ryu; Seungtaek Kim

doi:10.1002/jmv.26397

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Meehyun Ko, Sangeun Jeon, Wang Shick Ryu, Seungtaek Kim

Research output: Contribution to journal › Article › peer-review

59 Citations (Scopus)

Abstract

Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC₅₀ = 0.0022 µM).

Original language	English
Pages (from-to)	1403-1408
Number of pages	6
Journal	Journal of Medical Virology
Volume	93
Issue number	3
DOIs	https://doi.org/10.1002/jmv.26397
Publication status	Published - 2021 Mar

Bibliographical note

Funding Information:
The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF‐2017M3A9G6068245 and NRF‐2020M3E9A1041756).

Publisher Copyright:
© 2020 Wiley Periodicals LLC

All Science Journal Classification (ASJC) codes

Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jmv.26397

Cite this

@article{950d2aa0d00247ceb27ae8c1afbc0a6f,

title = "Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells",

abstract = "Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).",

author = "Meehyun Ko and Sangeun Jeon and Ryu, {Wang Shick} and Seungtaek Kim",

note = "Funding Information: The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF‐2017M3A9G6068245 and NRF‐2020M3E9A1041756). Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2021",

month = mar,

doi = "10.1002/jmv.26397",

language = "English",

volume = "93",

pages = "1403--1408",

journal = "Journal of Medical Virology",

issn = "0146-6615",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

AU - Ko, Meehyun

AU - Jeon, Sangeun

AU - Ryu, Wang Shick

AU - Kim, Seungtaek

N1 - Funding Information: The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF‐2017M3A9G6068245 and NRF‐2020M3E9A1041756). Publisher Copyright: © 2020 Wiley Periodicals LLC

PY - 2021/3

Y1 - 2021/3

N2 - Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).

AB - Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).

UR - http://www.scopus.com/inward/record.url?scp=85089391428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089391428&partnerID=8YFLogxK

U2 - 10.1002/jmv.26397

DO - 10.1002/jmv.26397

M3 - Article

C2 - 32767684

AN - SCOPUS:85089391428

SN - 0146-6615

VL - 93

SP - 1403

EP - 1408

JO - Journal of Medical Virology

JF - Journal of Medical Virology

IS - 3

ER -

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this